GWH heads into Thursday's Q1 re-release event with the stock at its lowest price in months and shorts already sitting on double-digit exposure to the float.
The week's central tension is clear: a savage post-earnings drop is still reverberating through the tape, short interest is well elevated and trending higher on a monthly basis, and another company event lands tomorrow. ESS Tech closed at $0.77 on Tuesday, down 33% on the week and down 5% on the day — a relentless drift lower following the Q1 miss reported on May 7, when the stock fell 31.6% in a single session. That loss came on top of a 9.7% drop after the March 5 Q4 print. The pattern is consistent: every quarterly result this year has sent the stock sharply lower.
Short positioning tells a story of sustained conviction rather than a new panic. SI has been climbing since mid-April, rising from roughly 6% of the float on April 17 to nearly 8% on May 12 — a month-on-month increase of about 20%. The absolute level of ~7.9% of the free float puts GWH in genuinely crowded territory for a company of this size. The lending market has actually loosened somewhat through this price decline: cost to borrow has eased to 2.9% from above 4% a month ago, its lowest point in weeks. Availability has shifted with it, and with utilisation now at 66% — well below the 52-week peak of 92% — there is room for the short base to grow without an immediate supply squeeze. The setup is one of orderly, low-friction short selling rather than a stressed borrow environment.
The Street has been consistently bearish for months. The most recent analyst action from Roth Capital in early March cut the target to $2.50 from $3.50 while maintaining a Buy. That $2.50 target sits more than three times above the current price, so while it technically represents upside, the rapid compression between that call and where the stock is trading underscores how badly execution has disappointed. Prior moves from Roth MKM, Baird, and Canaccord across 2025 all involved target cuts of 50% or more — a long, grinding pattern of downward revisions with no analyst yet calling a floor convincingly. There are no meaningful bull-case anchors in the data. The ORTEX short score of 63 and a short score rank in just the 6th percentile confirm that the quantitative overlay also reads this as a heavily shorted, poorly positioned name.
On the ownership side, the institutional register is thin and concentrated. SoftBank holds 8.6% of shares, Breakthrough Energy Ventures another 4.4%, and Honeywell 3.9% — all strategic holders with long-term mandates, none of them likely to provide near-term buying support. Alyeska and Arosa Capital initiated or added positions in the second half of 2025, but their entries were at materially higher prices. Insider activity over the past year has been exclusively sales — the Acting CEO and Acting CFO have sold small tranches every quarter at prices ranging from $4.81 down to $1.54, all below current analyst targets and all at levels above where the stock trades now.
The May 7 earnings call outlined a 5MW/50MWh pilot project called Project New Horizon, with delivery targeted for December 2027. That kind of extended timeline is unlikely to move the needle for a stock trading below $1.00 — the market appears focused on the widening gap between the company's long-duration iron-flow battery technology and near-term commercial delivery. Peers tell a mixed story: FLUX fell 21% on the week, broadly in line with GWH, while NPWR rallied 22% and EOSE gained 30%, suggesting idiosyncratic pain here rather than a sector-wide selloff.
With another event on the calendar for tomorrow, the next data point to watch is whether management provides any revision to revenue guidance or cash runway — those two numbers, more than any technology milestone update, are likely to determine whether short sellers add further to a position that has already been building steadily for six weeks.
See the live data behind this article on ORTEX.
Open GWH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
